EE439 Double Immune Checkpoint Inhibition as First-Line Treatment for BRAF-Mutant Advanced Melanoma: A Cost-Effectiveness Analysis from the Brazilian Private Healthcare System Perspective
Abstract
Authors
Rodrigo Pereira Milton Barros Gisele Marinho dos Santos Camila Finardi Roubik Thais Herrero Geraldino Leandro Ladislau Alves